X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27873) 27873
Newspaper Article (9762) 9762
Newsletter (3625) 3625
Web Resource (1053) 1053
Magazine Article (246) 246
Transcript (173) 173
Trade Publication Article (146) 146
Book Chapter (80) 80
Book / eBook (26) 26
Publication (18) 18
Dissertation (16) 16
Book Review (10) 10
Streaming Video (7) 7
Conference Proceeding (4) 4
Reference (3) 3
Government Document (1) 1
Journal / eJournal (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple myeloma (28153) 28153
humans (21188) 21188
oncology (11578) 11578
multiple myeloma - drug therapy (10249) 10249
hematology (9686) 9686
female (8931) 8931
male (8900) 8900
cancer (8899) 8899
middle aged (7892) 7892
aged (6779) 6779
multiple-myeloma (6281) 6281
research (5175) 5175
adult (4990) 4990
bortezomib (4846) 4846
care and treatment (4789) 4789
chemotherapy (4480) 4480
multiple myeloma - pathology (4040) 4040
animals (3997) 3997
apoptosis (3727) 3727
clinical trials (3692) 3692
drug therapy (3677) 3677
patients (3632) 3632
cancer therapies (3607) 3607
antineoplastic combined chemotherapy protocols - therapeutic use (3495) 3495
leukemia (3336) 3336
treatment outcome (3177) 3177
antineoplastic agents - therapeutic use (3135) 3135
pharmaceutical industry (3071) 3071
medical research (3035) 3035
lymphomas (3017) 3017
stem cells (2964) 2964
multiple myeloma - therapy (2945) 2945
therapy (2778) 2778
transplantation (2755) 2755
cell line, tumor (2683) 2683
dexamethasone (2675) 2675
bone marrow (2637) 2637
tumors (2605) 2605
proteins (2388) 2388
prognosis (2371) 2371
aged, 80 and over (2225) 2225
drug dosages (2192) 2192
survival (2177) 2177
multiple myeloma - complications (2176) 2176
mice (2150) 2150
thalidomide (2150) 2150
health aspects (2109) 2109
drugs (2062) 2062
analysis (2042) 2042
multiple myeloma - mortality (1909) 1909
antineoplastic agents - pharmacology (1896) 1896
multiple myeloma - metabolism (1885) 1885
immunotherapy (1812) 1812
immunology (1804) 1804
expression (1802) 1802
fda approval (1792) 1792
apoptosis - drug effects (1737) 1737
lenalidomide (1712) 1712
studies (1662) 1662
multiple myeloma - genetics (1652) 1652
multiple myeloma - diagnosis (1650) 1650
stem-cell transplantation (1622) 1622
pharmacology & pharmacy (1621) 1621
disease (1542) 1542
myeloma (1522) 1522
thalidomide - analogs & derivatives (1512) 1512
medicine, experimental (1507) 1507
risk factors (1459) 1459
gene expression (1452) 1452
transplants & implants (1437) 1437
thalidomide - therapeutic use (1394) 1394
earnings per share (1393) 1393
medicine & public health (1393) 1393
retrospective studies (1389) 1389
drug resistance (1387) 1387
dexamethasone - administration & dosage (1356) 1356
metastasis (1354) 1354
medicine (1344) 1344
research & development--r&d (1330) 1330
hematology, oncology and palliative medicine (1307) 1307
cell biology (1268) 1268
multiple myeloma - immunology (1262) 1262
antigens (1254) 1254
transplantation, autologous (1229) 1229
diagnosis (1221) 1221
thalidomide - administration & dosage (1221) 1221
genetic aspects (1213) 1213
development and progression (1208) 1208
medical prognosis (1179) 1179
cytotoxicity (1154) 1154
cells (1150) 1150
kinases (1134) 1134
antineoplastic agents - adverse effects (1121) 1121
signal transduction (1101) 1101
dose-response relationship, drug (1097) 1097
antineoplastic combined chemotherapy protocols - adverse effects (1087) 1087
lymphocytes (1084) 1084
biotechnology industry (1083) 1083
recurrence (1076) 1076
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (41529) 41529
Japanese (437) 437
French (296) 296
German (226) 226
Chinese (171) 171
Russian (139) 139
Spanish (132) 132
Polish (82) 82
Italian (74) 74
Czech (53) 53
Dutch (27) 27
Hungarian (21) 21
Danish (15) 15
Swedish (15) 15
Norwegian (13) 13
Hebrew (11) 11
Finnish (10) 10
Korean (8) 8
Portuguese (8) 8
Serbian (7) 7
Slovak (6) 6
Turkish (5) 5
Ukrainian (3) 3
Bulgarian (2) 2
Croatian (2) 2
Arabic (1) 1
Romanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2009, Volume 374, Issue 9686, pp. 324 - 339
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 18, pp. 2347 - 2357
Purpose The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM... 
ZOLEDRONIC ACID | ONCOLOGY | VERTEBRAL AUGMENTATION | SKELETAL-RELATED EVENTS | DOUBLE-BLIND | UNDETERMINED SIGNIFICANCE | RANDOMIZED-TRIAL | MONOCLONAL GAMMOPATHY | SPINAL-CORD COMPRESSION | VITAMIN-D DEFICIENCY | PERCUTANEOUS VERTEBROPLASTY | Outcome Assessment (Health Care) - methods | Humans | Imidazoles - administration & dosage | Tomography, X-Ray Computed | Positron-Emission Tomography | Fractures, Bone - diagnosis | Medical Oncology - organization & administration | Multiple Myeloma - drug therapy | Bone Diseases - drug therapy | Diphosphonates - therapeutic use | Imidazoles - therapeutic use | Drug Therapy, Combination | Osteonecrosis - diagnosis | Bone Diseases - complications | Multiple Myeloma - complications | Bone Density Conservation Agents - therapeutic use | Bone Diseases - radiotherapy | Combined Modality Therapy | Diphosphonates - administration & dosage | International Cooperation | Bone Density Conservation Agents - administration & dosage | Magnetic Resonance Imaging | Administration, Intravenous | Radiotherapy - methods | Clodronic Acid - therapeutic use | Clodronic Acid - administration & dosage | Multiple Myeloma - radiotherapy | Osteonecrosis - prevention & control | Fractures, Bone - prevention & control | Practice Guidelines as Topic | Index Medicus | Hema20 | Gdln2 | Bone5 | Special | Hema23 | Hema22 | Hema21
Journal Article
Leukemia, ISSN 1476-5551, 2013, Volume 28, Issue 3, pp. 525 - 542
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 7, pp. 621 - 631
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 17, pp. 1621 - 1634
... of therapy for multiple myeloma. 3 In phase 3 studies, triplet regimens based on these agents were shown to be more efficacious than doublet regimens when these regimens were used as a first-line treatment 4... 
SUPERIORITY | MEDICINE, GENERAL & INTERNAL | CARFILZOMIB | RANDOMIZED PHASE-3 | THERAPY | PROTEASOME INHIBITOR MLN9708 | QUALITY-OF-LIFE | BORTEZOMIB | THALIDOMIDE | ANTITUMOR-ACTIVITY | TRANSPLANTATION | Glycine - analogs & derivatives | Glycine - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Boron Compounds - administration & dosage | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Exanthema - chemically induced | Aged, 80 and over | Adult | Glycine - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Proportional Hazards Models | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Boron Compounds - adverse effects | Aged | Care and treatment | Dosage and administration | Dexamethasone | Multiple myeloma | Thrombocytopenia | Inhibitor drugs | Drug therapy | Peripheral neuropathy | Survival | Patients | Drug dosages | Proteasome inhibitors | Quality of life | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
...) with multiple myeloma who were previously treated with at least three lines of therapy (including proteasome inhibitors and immunomodulatory drugs... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | RISK | MULTICENTER | THERAPY | ELOTUZUMAB | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Evidence-based medicine | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Inhibitors | Interactive systems | Response rates
Journal Article